

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if known</b> Application Number 10/516,705-Conf. #1003 Filing Date December 2, 2004 First Named Inventor Takahito Hara Art Unit 1643 Examiner Name L. A. Bristol Attorney Docket Number 68138/46590	
Sheet	1	of	2		

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.4). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: September 4, 2009

Electronic Signature for Colleen McKiernan, Ph.D.: /Colleen McKiernan, Ph.D./

Substitute for form 1449/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 30%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/516,705-Conf. #1003</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">December 2, 2004</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Takahito Hara</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">1643</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">L. A. Bristol</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">68138/46590</td> </tr> </table>		Complete if Known		Application Number	10/516,705-Conf. #1003	Filing Date	December 2, 2004	First Named Inventor	Takahito Hara	Art Unit	1643	Examiner Name	L. A. Bristol	Attorney Docket Number	68138/46590
Complete if Known																	
Application Number	10/516,705-Conf. #1003																
Filing Date	December 2, 2004																
First Named Inventor	Takahito Hara																
Art Unit	1643																
Examiner Name	L. A. Bristol																
Attorney Docket Number	68138/46590																
Sheet	2	of	2														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Sun et al., "Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes," <i>Nucleic Acids Research</i> (1997), 25(16):3318-3325	
	CB	Suzuki et al., "Coexpression of the Partial Androgen Receptor Enhances the Efficacy of Prostate-specific Antigen Promoter-driven Suicide Gene Therapy for Prostate," <i>Cancer Research</i> (2001), 61:1276-1279	
	CC	Zhu et al., "Androgen-Dependent Transcriptional Regulation of the Prostate-Specific Antigen Gene by Thyroid Hormone 3,5,3'-L-triiodothyronine," <i>Journal of Andrology</i> (2001), 22(1):136-141	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.